Rani Therapeutics to sell 3M shares at $3.00 in registered direct offering [Seeking Alpha]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Seeking Alpha
common stock and pre-funded warrants to purchase 0.33M shares , together with Series C common warrants to purchase up to an aggregate of 3.33M shares, in a registered direct offering. Each share of Common Stock is being sold together with one Series C common warrant at a combined purchase price of $3.00. The Series C common warrants will have an exercise price of $3.00 per share and will expire 5 years from the date of issuance. The Co. has also entered into an agreement with the investor to cancel all outstanding Series A common warrants to purchase an aggregate of 3.25M shares of the Co.'s common stock, previously issued on July 22, 2024. The gross proceeds to Rani Therapeutics from this offering are expected to be ~$10M. Shares to $2.61. More on Rani Therapeutics Rani Therapeutics prices securities offering to raise $10 million Seeking Alpha's Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics Financial information for Rani Therapeu
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin TriagonistGlobeNewswire
- Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing WarrantsGlobeNewswire
- Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
- Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock [Yahoo! Finance]Yahoo! Finance
RANI
Earnings
- 8/6/24 - Beat
RANI
Analyst Actions
- 10/18/24 - HC Wainwright
RANI
Sec Filings
- 10/17/24 - Form SC
- 10/17/24 - Form 4
- 10/16/24 - Form 8-K
- RANI's page on the SEC website